Assessment of sulphasalazine as a treatment modality in Sjögren's disease in NZB/NZW F1 hybrid mice

Clinical and Experimental Rheumatology

Volumn 14, Issue 1, 1996, Pages 53-57

  Yeoman, C M ^a,b   Franklin, C D ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

NZB NZW F1 hybrid mouse; Sj gren's syndrome; Sulphasalazine

Indexed keywords

SALAZOSULFAPYRIDINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; LYMPHOCYTIC INFILTRATION; MODEL; MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SJOEGREN SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; LACRIMAL APPARATUS; MALE; MICE; MICE, INBRED NZB; SJOGREN'S SYNDROME; SUBMANDIBULAR GLAND; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0030011980     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. STRAND V, TALAL N: Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis 1980; 30: 1046-52.
2. SHEARN MA: Sjögren's syndrome. Med Clin North Am 1977; 61: 271-82.
3. ALSPAUGH MA, WHALEY K: Sjögren's syndrome. In KELLY WN, HARRIS ED, RUDDY S, SLEDGE CB (Eds.): Textbook of Rheumatology, Philadelphia, W.B. Saunders Co, 1981: 971-99.
4. COLL J, RIVES A, GRINO MC, SETOAIN J, VIVANCOS J, BALCELLS A: Prevalence of Sjögren's syndrome in autoimmune diseases. Ann Rheum Dis 1987; 46: 286-9.
5. TALAL N: Sjögren's syndrome. In COHEN AS (Ed.): Rheumatology and Immunology, New York, Grune & Stratton, 1979: 297-83.
6. KESSLER HS: A laboratory model for Sjögren's syndrome. Am J Pathol 1968; 52: 671-8.
7. SCHOT LPC, VERHEUL HAM, SCHUURS AHWM: Effect of nandrolone decanoate on Sjögren's syndrome-like disorders in NZB/NZW mice. Clin Exp Immunol 1984; 57: 571-4.
8. YEOMAN CM, FRANKLIN CD: The treatment of Sjögren's disease in NZB/NZW F1 hybrid mice with azathioprine: a two-stage study. Clin Exp Rheumatol 1994; 12: 49-54.
9. SVARTZ N: Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 1942; 110: 577-98.
10. SINCLAIR RJG, DUTHIE JJR: Salazopyrin in the treatment of rheumatoid arthritis. Ann Rheum Dis 1948; 8: 226-31.
11. NEUMAN VC, GRINDULIS KA, HUBBALL S, MCCONKEY B, WRIGHT V: Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Br Med J 1983; 287: 1099-102.
12. PULLAR T, HUNTER JA, CAPELL HA: Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 1983; 287: 1102-4.
13. YEOMAN CM: Preliminary study into Sjögren's disease in mice to assess the staging of the disease prior to chemotherapy. J Dent Res 1987; 500.
14. ELIAS H, HENNIG A, SCHWARTZ DE: Sterology: Applications to biomedical research. Physiol Rev 1971; 51: 158-200.
15. BAX DE: Sulfonamides. In DIXON JS, FURST DE (Eds.): Second-Line Agents in the Treatment of Rheumatic Diseases, NY-Basel-Hong Kong, Marcel Dekker Inc., 1992: 267-86.
16. VERHEUL HAM: Effects of tibolone, lynestrenol, ethylestrenol and desogestrel on autoimmune disorders in NZB/ NZW mice. Clin Immunol Immunopathol 1986; 38: 198-208.
17. BACH MA et al.: Effect of long term treatment with circulating thymic factor on murine lupus. Arthritis Rheum 1980; 23: 1351-8.